While exosomes loaded with OXA or gal-9 siRNA were unsuccessful in restraining tumor growth alone, their combination regimen significantly decreased tumor size and prolonged survival relative to the effects of the conventional chemotherapeutic agent gemcitabine (Zhou et al., 2021). The gene discussed is LGALS9; the disease is neoplasm.